In vitro and in vivo efficacy of non-psychoactive cannabidiol in neuroblastoma.

Author(s): Fisher T, Golan H, Schiby G, PriChen S, Smoum R, Moshe I, Peshes-Yaloz N, Castiel A, Waldman D, Gallily R, Mechoulam R, Toren A

Pediatric Hemato-Oncology Research Laboratory, Sheba Cancer Research Center / Pediatric Hemato-Oncology Research Laboratory, Sheba Cancer Research Center; Department of Pediatric Hemato-Oncology, The Edmond and Lily Safra Children's Hospital / Department of Pathology, The Chaim Sheba Medical Center, Tel-Hashomer, Israel / Pediatric Stem Cell Research Institute, The Chaim Sheba Medical Center, Tel-Hashomer, Israel / Institute for Drug Research, Hebrew University of Jerusalem, Jerusalem, Israel / Cancer Research Center, The Chaim Sheba Medical Center, Tel-Hashomer, Israel / The Lautenberg Center for General and Tumour Immunology, Hebrew University of Jerusalem, Jerusalem, Israel / Department of Pediatric Hemato-Oncology, The Edmond and Lily Safra Children's Hospital; Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel.

Subject: Cancer View the study

Abstract:

Neuroblastoma (nbl) is one of the most common solid cancers in children. Prognosis in advanced nbl is still poor despite aggressive multimodality therapy. Furthermore, survivors experience severe long-term multi-organ sequelae. Hence, the identification of new therapeutic strategies is of utmost importance. Cannabinoids and their derivatives have been used for years in folk medicine and later in the field of palliative care. Recently, they were found to show pharmacologic activity in cancer, including cytostatic, apoptotic, and antiangiogenic effects.

Source: Current Oncology
Share Tweet

More medical studies related to Cancer:

View all medical studies >>

Subscribe for daily cannabis news, announcements, and business insights.

автоматический полив киев

https://topobzor.info